AC Immune SA at SVB Securities Global Biopharma Conference (Virtual) Transcript
Okay. Good morning, everybody. Welcome back to our next session of the SVB Securities Healthcare Conference. I'm Marc Goodman, one of the analysts here.
We're lucky enough to have the CEO of AC Immune, Andrea Pfeifer, with us. She's a Co-Founder of the company, which I believe was about 20 or so years ago, so something's been around. We've been tracking AC Immune for years now. We find them to be a leader in the space regarding science in Alzheimer's, diverse portfolio of candidates, multiple strong partnerships. So we've always been a big fan of what they're doing. Andrea is going to make some opening comments with slides, and then we'll have some time for questions afterwards.
Andrea, thank you so much for joining us again this year, and I'll turn it over to you.
Yep, good morning. I'm excited to be here and talk about AC Immune, a company pioneering precision medicine in neurodegenerative diseases. Today, we'll take a very quick overview,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |